الفهرس 
IntroductionOnly 14 pages are availabe for public view
 |  | from | 133 |  |  |
| | | from | 133 | | |
Abstract
Sepsis, a syndrome of physiologic, pathologic, and biochemical abnormalities induced by infection, is a major public health concern. Sepsis is a multifaceted host response to an infecting pathogen that may be significantly amplified by endogenous factors. The reported incidence of sepsis is increasing, reflecting greater recognition. Neonatal sepsis refers to an infection involving bloodstream in newborn infants less than 28 days old. It continues to remain a leading cause of morbidity and mortality among infants, especially in middle and low-income countries Since inflammation and inflammatory mediators play a crucial role in the pathophysiology of sepsis, anti-inflammatory treatment has become a prominent measure. Montelukast, is a leukotriene receptor antagonists and synthesis inhibitors. Antileukotriens drugs are a new class of anti-inflammatory drugs that have shown efficacy in the treatment of several inflammatory models. The aim of work: The study aimed to investigate the effect of montelukast on sepsis in the neonatal period in human. Material and method : A prospective , open labeled , randomized controlled trial conducted on 40 newborn admitted to NICU with diagnosis of neonatal sepsis at Mansoura University Children’s Hospital and at Mansoura Insurance Hospital from July 2017 to July 2018. The study included newborn with gestional age 34 weeks or more with clinical evidence of neonatal sepsis with exclusion of Babies presented initially with septic shock or DIC or MODS.The studied neonates were classified into two groups: Both groups were on the same protocol of treatment of sepsis and other supportive measures a